Impact of skeletal complications on patients' quality of life, mobility, and functional independence

被引:190
作者
Costa, Luis [1 ]
Badia, Xavier [2 ]
Chow, Edward [3 ]
Lipton, Allan [4 ]
Wardley, Andrew [5 ]
机构
[1] Hosp Santa Maria, Serv Oncol, Inst Med Mol Lisboa, P-1649039 Lisbon, Portugal
[2] Hlth Econ & Outcomes Res, Barcelona 08034, Spain
[3] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada
[4] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[5] Christie Hosp NHS Fdn Trust, Canc Res Dept Med Oncol, Manchester M20 4BX, Lancs, England
关键词
bone metastases; bone pain; breast cancer; prostate cancer; zoledronic acid;
D O I
10.1007/s00520-008-0418-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Introduction Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. Discussion Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.
引用
收藏
页码:879 / 889
页数:11
相关论文
共 78 条
[1]
THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]
Adrover E, 2005, J OUTCOMES RES, V9, P15
[3]
Arianayagam M, 2007, AUST FAM PHYSICIAN, V36, P737
[4]
EAU guidelines on prostate cancer [J].
Aus, G ;
Abbou, CC ;
Bolla, M ;
Heidenreich, A ;
Schmid, HP ;
van Poppel, H ;
Wolff, J ;
Zattoni, F .
EUROPEAN UROLOGY, 2005, 48 (04) :546-551
[5]
Changes in quality of life during palliative chemotherapy for solid cancer [J].
Bang, SM ;
Park, SH ;
Kang, HG ;
Jue, JI ;
Cho, IH ;
Yun, YH ;
Cho, EK ;
Shin, DB ;
Lee, JH .
SUPPORTIVE CARE IN CANCER, 2005, 13 (07) :515-521
[6]
Perception, assessment, treatment, and management of pain in the elderly [J].
Barkin, RL ;
Barkin, SJ ;
Barkin, DS .
CLINICS IN GERIATRIC MEDICINE, 2005, 21 (03) :465-+
[7]
American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].
Berenson, JR ;
Hillner, BE ;
Kyle, RA ;
Anderson, K ;
Lipton, A ;
Yee, GC ;
Biermann, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736
[8]
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[9]
Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone [J].
Berry, Donna L. ;
Moinpour, Carol M. ;
Jiang, Caroline S. ;
Ankerst, Donna Pauler ;
Petrylak, Daniel P. ;
Vinson, Lynne V. ;
Lara, Primo N. ;
Jones, Sharon ;
Taplin, Mary E. ;
Burch, Patrick A. ;
Hussain, Maha H. A. ;
Crawford, E. David .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2828-2835
[10]
Quality of life in post-menopausal osteoporosis [J].
Bianchi M.L. ;
Orsini M.R. ;
Saraifoger S. ;
Ortolani S. ;
Radaelli G. ;
Betti S. .
Health and Quality of Life Outcomes, 3 (1)